Your browser doesn't support javascript.
loading
Prediction of PSA Response after Dexamethasone Switch during Abiraterone Acetate + Prednisolone Treatment of Metastatic Castration-Resistant Prostate Cancer Patients.
Fekete, Bertalan; Biró, Krisztina; Gyergyay, Fruzsina; Polk, Nándor; Horváth, Orsolya; Géczi, Lajos; Patócs, Attila; Budai, Barna.
Afiliación
  • Fekete B; Department of Endocrinology and Diabetology, Internal Medicine II, Central Hospital of Northern Pest-Military Hospital, Podmaniczky u. 109-111, 1062 Budapest, Hungary.
  • Biró K; Department of Genitourinary Medical Oncology and Clinical Pharmacology, National Institute of Oncology, Comprehensive Cancer Center, Ráth Gy. u. 7-9, 1122 Budapest, Hungary.
  • Gyergyay F; Department of Genitourinary Medical Oncology and Clinical Pharmacology, National Institute of Oncology, Comprehensive Cancer Center, Ráth Gy. u. 7-9, 1122 Budapest, Hungary.
  • Polk N; Department of Visceral Surgery, National Institute of Oncology, Comprehensive Cancer Center, Ráth Gy. u. 7-9, 1122 Budapest, Hungary.
  • Horváth O; Department of Genitourinary Medical Oncology and Clinical Pharmacology, National Institute of Oncology, Comprehensive Cancer Center, Ráth Gy. u. 7-9, 1122 Budapest, Hungary.
  • Géczi L; Department of Genitourinary Medical Oncology and Clinical Pharmacology, National Institute of Oncology, Comprehensive Cancer Center, Ráth Gy. u. 7-9, 1122 Budapest, Hungary.
  • Patócs A; National Tumor Biology Laboratory, National Institute of Oncology, Comprehensive Cancer Center, Ráth Gy. u. 7-9, 1122 Budapest, Hungary.
  • Budai B; National Tumor Biology Laboratory, National Institute of Oncology, Comprehensive Cancer Center, Ráth Gy. u. 7-9, 1122 Budapest, Hungary.
Cancers (Basel) ; 16(15)2024 Aug 03.
Article en En | MEDLINE | ID: mdl-39123487
ABSTRACT

BACKGROUND:

The aim was to elaborate a predictive model to find responders for the corticosteroid switch (from prednisolone to dexamethasone) at the first prostate-specific antigen (PSA) progression (≥25% increase) during abiraterone acetate (AA) treatment of metastatic castration-resistant prostate cancer (mCRPC) patients.

METHODS:

If PSA has decreased (≥25%) after switch, patients were considered responders. Logistic regression of 19 dichotomized parameters from routine laboratory and patients' history was used to find the best model in a cohort of 67 patients. The model was validated in another cohort of 42 patients.

RESULTS:

The model provided 92.5% and 90.5% accuracy in the testing and the validation cohorts, respectively. Overall the accuracy was 91.7%. The AUC of ROC curve was 0.92 (95% CI 0.85-0.96). After a median follow-up of 27.9 (26.3-84) months, the median AA+dexamethasone treatment duration (TD) in non-responders and responders was 4.7 (3.1-6.5) and 11.1 (8.5-12.9) months and the median overall survival (OS) was 23.2 (15.6-25.8) and 33.5 (26.1-38) months, respectively. Multivariate Cox regression revealed that responsiveness was an independent marker of TD and OS.

CONCLUSIONS:

A high accuracy model was developed for mCRPC patients in predicting cases which might benefit from the switch. For non-responders, induction of the next systemic treatment is indicated.
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Cancers (Basel) Año: 2024 Tipo del documento: Article País de afiliación: Hungria Pais de publicación: Suiza
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Cancers (Basel) Año: 2024 Tipo del documento: Article País de afiliación: Hungria Pais de publicación: Suiza